Multigene Signature Panels and Breast Cancer Therapy: Patterns of Use and Impact on Clinical Decision Making Neal Bhutiani, MD, Michael E. Egger, MD, MPH, Nicolás Ajkay, MD, FACS, Charles R. Scoggins, MD, MBA, FACS, Robert CG. Martin, MD, PhD, FACS, Kelly M. McMasters, MD, PhD, FACS Journal of the American College of Surgeons Volume 226, Issue 4, Pages 406-412.e1 (April 2018) DOI: 10.1016/j.jamcollsurg.2017.12.043 Copyright © 2018 American College of Surgeons Terms and Conditions
Figure 1 Multigene signature panel (MSP) use over time (2011 to 2014). Use of MSPs increased annually during the study period. Journal of the American College of Surgeons 2018 226, 406-412.e1DOI: (10.1016/j.jamcollsurg.2017.12.043) Copyright © 2018 American College of Surgeons Terms and Conditions
Figure 2 Trends in type of multigene signature panel (MSP) used over time (2011 to 2014). Oncotype DX remained the most frequently used MSP during the study period, though the proportional use of MammaPrint increased over time. Journal of the American College of Surgeons 2018 226, 406-412.e1DOI: (10.1016/j.jamcollsurg.2017.12.043) Copyright © 2018 American College of Surgeons Terms and Conditions
eFigure 1 Filter strategy for acquisition of study dataset. ER, estrogen receptor; MSP, multigene signature panel. Journal of the American College of Surgeons 2018 226, 406-412.e1DOI: (10.1016/j.jamcollsurg.2017.12.043) Copyright © 2018 American College of Surgeons Terms and Conditions